313 - Docetaxel in the treatment of breast cancer: a multicenter retrospective study from china

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Breast Cancer
Biological Therapy
Presenter Binghe Xu
Authors B. Xu
  • Medical Dept., Cancer Hospital, Chinese Academy of Medical Sciences, 100021 - Beijing/CN



Docetaxel is considered as a fundamental drug in the treatment of breast cancer. It has been extensively incorporated into the neoadjuvant, adjuvant and metastatic treatment. The aim of this study was to investigate how breast cancer patients are treated with docetaxel in China.


A retrospective review of chemotherapy with docetaxel performed from 2009 to 2011 was carried out in China. Study included all patients diagnosed with invasive breast cancer and treated with docetaxel-containing regimens in forty-two cancer centers from 12 provinces in China. Regimens were compared in different subgroups based on stage, subtype, and lymph node (LN) status. Patterns of chemotherapy were also compared to published guidelines.


Among 2188 breast cancer patients treated with docetaxel, 1881 (86.0%) were in adjuvant or/and neoadjuvant setting (including 91 in both settings). The mean age was 48.7 (range, 14-82). Compared with 288 patients using docetaxel as single agent therapy, more patients (86.8%) used docetaxel-containing combination regimens. The mean cycle administered and dose for every cycle was 4.8 and 73.0 mg/m2, respectively. Dose reduction and delay occurred in 409 (19.7%) patients mainly due to non-medical factors (10.9%) and hematologic toxicity (5.9%). TAC, TA, TC, TX, and AC-T regimens were given in 34.8%, 19.7%, 17.4%, 5.3%, and 2.2% of patients respectively. TAC was used more frequently in triple-negative breast cancer (TNBC) than other patients (43.0% vs. 32.7%, P = 0.004). In the (neo)adjuvant setting, TAC regimen was used more frequently in LN-positive patients than LN-negative group (44.2% vs. 30.0%, P < 0.001). Of 1682 patients in adjuvant setting, 729 (43.3%) were treated with triplet (TAC or AC-T). In 290 patients receiving neoadjuvant chemotherapy, only 94 (32.4%) used TAC and none used AC-T (P = 0.013).


Docetaxel was widely used in the treatment of breast cancer in China, especially in the (neo)adjuvant setting. TAC regimen was the most frequent option, especially in patients with TNBC or LN-positive BC. Although AC-T was also recommended in adjuvant setting by most guidelines, it was less commonly used compared to TAC regimen in China.


All authors have declared no conflicts of interest.